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Angiotensin II has mitogenic and angiogenic effects and its receptors are widespread, particularly in epithelial tissue. Tissue
renin angiotensin systems (tRASs) may be a local source of angiotensin II that has specific paracrine functions. To investigate
the presence of a tRAS in normal human breast and tumours. Immunocytochemistry, and quantitative RT–PCR was used to
establish: (i) the presence and localisation of RAS components, (ii) the possibility of their involvement in cancer. (1) mRNA coding for
angiotensinogen, prorenin, angiotensin converting enzyme (ACE), and both AT1 and AT2 receptors was demonstrated in normal
and diseased breast tissues. (2) (pro)renin was identified in epithelial cells in both normal and diseased tissue, but in invasive
carcinoma, its distribution was mostly confined to fibroblasts or could not be detected at all. (3) Angiotensin converting enzyme was
shown in epithelial cells in both normal and malignant tissue. The results are consistent with the hypothesis that a tRAS is present in
the breast, and is disrupted in invasive cancer.
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The renin angiotensin system (RAS) has received most attention in
relation to its functions in the circulation, in which the genera-
tion of the active hormone, angiotensin II (Ang II), is associated
with the regulation of aldosterone secretion, salt and water
metabolism and blood pressure (Mulrow, 1999; Kaschina and
Unger, 2003). In recent years, attention has also focused on the
evidence for widespread local tRASs (Mulrow and Franco-Saenz,
1996; Vinson et al, 1997; Tahmasebi et al, 1999; Nielsen et al, 2000;
Li et al, 2004).
Angiotensin types 1 and 2 (AT1 and AT2) receptors are present
in many different tissue types, and in particular, the AT1 receptor
is abundant in secretory epithelial tissue (Vinson et al, 1995, 1997;
Marsigliante et al, 1996). As Ang II and tRASs may have an
important role in tissue growth and modelling these observations
lead to the possibility that tRASs are involved in cancer.
While Ang II has been used in cancer to enable better
accessibility of chemotherapeutic drugs to the tumour (Noguchi
et al, 1988), Ang II blockers and ACE inhibitors have never-
theless been shown to reduce tumour size, angiogenesis and
metastasis (Fujita et al, 2002; Uemura et al, 2005), although the
suggestion that long-term use of angiotensin converting enzyme
(ACE) inhibitors in patients may limit the development of cancer
(Lever et al, 1998) has been questioned (Li et al, 2003; Ronquist
et al, 2004).
Tahmasebi et al (1998) showed the transcription of (pro)renin
in fibroblasts and myoepithelial cells in normal and abnormal
breast tissue, suggesting the existence of a tRAS within the
breast. The generation of Ang II within the breast would support
the hypothesis that Ang II could directly or indirectly contribute
to breast cancer progression (Inwang et al, 1997; Tahmasebi et al,
1998; De Paepe et al, 2001).
Using immunocytochemistry, and real time RT–PCR, the
present study addresses the possibility that a tRAS exists in
normal and cancerous breast tissue,
MATERIALS AND METHODS
Quantitative RT–PCR
Quantitative RT–PCR (QRT–PCR) was carried out using Taqman
fluorogenic probe and primers specific for angiotensinogen,
prorenin, ACE and the angiotensin receptors (AT1 and AT2)
(Applied Biosystems, Warrington, UK). Total RNA from normal
human liver, kidney and lung (BD Biosciences, Clontech, Oxford,
UK) were used to set up standard curves for each gene as
appropriate (five-fold serial dilutions ranging from 0.4 to 250ng
of total RNA per reaction, in triplicate). Values for normal breast
and breast tumour (infiltrating ductal carcinoma) (BD Bio-
sciences, Clontech) were obtained as anoograns RNA equivalents
of the reference gene in each case derived from the corresponding
standard curve. Reverse transcription and PCR amplification were
performed in an MX3000P real time PCR system (Stratagene) using
SuperScript
TM III one-step qRT–PCR reagent (Invitrogen, Paisley,
UK) under the reaction conditions described in Table 1. Nuclease-
free water was used in place of RNA template as a nontemplate
control (NTC).
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Formalin-fixed, paraffin wax-embedded and frozen human tissue
sections: Human breast tissue samples were provided with
appropriate informed consent from patients undergoing surgery.
Ethical approval was granted from the Local Ethical Committee.
Patients undergoing breast surgery (mean age 58 years), included
normal breast tissue and benign (23 patients), premalignant and
malignant breast lesions (77 patients). Paraffin wax-embedded
and frozen tissues were generously provided by Dr C Brown
(Department of Morbid Anatomy, Royal Hospitals Trust, London)
and Ms S Jones (Department of pathology, St Bartholomew’s
Hospital, London) respectively.
Antibodies: The monoclonal anti-renin mouse IgG antibody
2D12 was a gift from Professor Pierre Corvol (Colle `ge de France,
Paris) and the polyclonal anti-ACE mouse IgG, from Chemicon
International Inc (Hampshire,UK) Anti-vimentin (mouse IgM),
anti-cytokeratin (mouse IgG) and anti-actin mouse (IgG) anti-
bodies (Sigma, Poole, Dorset, UK) were used to discriminate
between fibroblasts, epithelial cells and myoepithelium, respec-
tively. Other reagents were from Sigma unless stated otherwise.
Avidin-biotin immunodetection-frozen tissue sections: Frozen
tissue sections (4–8mm) were fixed with acetone on poly-L-lysine-
coated slides and fixed in cold acetone, washed in three changes of
Tris-buffered saline (TBS, pH 7.6, 50mmol Tris/l, 150mmol NaCl/
l, 2mmol MgCl2/l pH 7.4) and incubated for 5–10min in hydrogen
peroxide (0.1–1%) in TBS. Finally, sections were washed in
TBS twice for 5min at room temperature. Nonspecific antibody
binding was blocked with 1% (w/v) normal rabbit blocking
reagents (Boehringer Mannheim, Germany) and the sections were
incubated with their respective primary antibodies for either
90min at room temperature or overnight at 41C in a humidifica-
tion chamber. Negative control samples were incubated with
TBS buffer alone. Unbound antibody was removed by washing
3  for 3min in TBS. Specific binding was detected by incubating
the sections with secondary biotin-conjugated antibody, rabbit
anti-mouse IgG, (1:300–1:400; DAKO, Cambridgeshire, UK)
for 30min and amplified using an avidin/streptavidin, biotiny-
lated enzyme complex (ABC) system (DAKO) according to the
manufacturers instructions followed by visualisation using
diaminobenzidine hydrochloride (DAB, 3,30-diaminobenzidine).
Sections were counter-stained using Harris haematoxylin (VWR,
Poole, UK) destained in acid alcohol (10ml 1% HCl in 990ml
of 70% industrial methylated spirit (IMS; VWR). Sections were
dehydrated by washing in 95% alcohol, 100% alcohol (2 1min),
and finally xylene, (2 3min) prior to mounting in Depax
mounting medium (VWR).
Avidin–biotin immunodetection-paraffin wax embedded sec-
tions: Waxed embedded tissue sections were washed in xylene,
3 5min and rinsed in 100, 90 and 80% alcohol (2 2min washes
each). To block endogenous peroxidase activity, sections were
incubated in 3% hydrogen peroxide (v/v), diluted in methanol for
15min at room temparature. Sections were washed in distilled
water for 10min and microwaved (700W) for 16min in
10mmoll
 1 citrate buffer. Immunostaining was carried out at as
previously described.
Breast cancer cell lines fixed on to the poly-L-lysine slides: MCF-7
and T47-D breast cancer cell lines were purchased from European
Collection of Animal Cell Cultures (ECACC; Salisbury, UK) and
routinely cultured (Puddefoot et al, 2002). Cells were harvested
and seeded on to poly-L-lysine coated slides, then incubated at 371
under 5% CO2 for 24h in a serum-free medium.
Slides were washed briefly with TBS (pH 7.6) (2 1min), then




AT1 and AT2 receptors Values for AT1 and AT2 receptor
mRNA expression were obtained by reference to a standard
curve generated using normal human kidney total RNA. Normal
breast tissue gave a value for AT1 receptor mRNA comparable
to that found in human kidney or lung, however, the
breast tumour sample showed a much higher abundance of AT1
receptor mRNA, 10-fold higher than found in normal breast tissue
(Figure 1A).
Table 1 Thermal cycling parameters for qRT–PCR
QRTPCR parameters
PCR amplification cycles
Initial steps Melt Anneal/extend
30min 10min 15s 30s









































Figure 1 Quantitative result for AT1 (A) and AT2 (B) receptor mRNA
transcription using real time reverse transcriptase–polymerase chain
reaction (qRT–PCR) in normal breast tissue and infiltrating ductal
carcinoma. Samples used contained 75ng total RNA from normal breast
and tumour tissue.
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sAT2 mRNA was barely detectable in normal breast tissue, but it
was clearly present in breast tumour, albeit at lower levels than in
either kidney or lung (Figure 1B). Nontemplate control tubes gave
no detectable amplification.
RAS components Values for angiotensinogen (AGT), prorenin
and ACE mRNA expression were obtained by reference to
standards curves generated using normal human liver, kidney
and lung total RNA, respectively. AGT mRNA was detected at
relatively low, although significant levels in both normal breast and
in breast tumour samples. Nontemplate control tubes gave no
detectable amplification. There was no significant difference
between the levels of AGT mRNA found in normal and breast
tumour tissue (Figure 2A).
Prorenin mRNA was also present in both normal breast and
breast tumour samples and although values were relatively low,
significantly higher levels were detected in normal compared to
breast tumour tissue (Figure 2A).
ACE mRNA was also lower in tumour tissue compared with
normal tissue (Figure 2B). In both cases, nontemplate control
tubes gave no detectable amplification.
Immunocytochemistry Cellular identification was confirmed by refe-
rence to slides immunostained for cytokeratin (epithelial cells), actin
(myoepithelial cells), and vimentin (fibroblasts) (results not shown).
(pro)renin In normal tissue sections, immunoreactive (pro)renin
was shown to be distributed almost exclusively in myoepithelial cells
(Figure 3A), and connective tissue while epithelial cells showed
virtually no staining. In contrast, in fibroadenoma tissue, (pro)renin
was now found to be localised in epithelial cells (Figure 3C), as well
as in myoepithelial cells, and stromal fibroblasts and connective
tissue. Control sections in the absence of primary antibody (Figure
3 Ba n dD )s h o w e dn oi m m u n o s t a i n i n g .
In malignant tumours, most of the (pro)renin staining was seen
in myoepithelial cells with, some patchy staining in epithelial cells,
and also in fibroblasts.
In ductal carcinoma in situ, positive (pro)renin staining was
observed in the myoepithelial cells and fibroblasts as a disrupted














































Figure 2 Quantitative result for angiotensinogen, prorenin and ACE
mRNA transcription using real time reverse transcriptase–polymerase
chain reaction (qRT–PCR) in normal breast tissue and infiltrating ductal
carcinoma. Samples used contained 250ng total RNA from normal breast
and tumour tissue for angiotensinogen and prorenin (A), and 75ng total
RNA from normal breast and tumour tissue for ACE (B).
Figure 3 (Pro)renin was localised in sections of formalin-fixed, paraffin-embedded normal breast tissue. (A) Immunoperoxidase staining shows the
antigen (pro)renin was present in myoepithelial cells (red arrow). Staining was absent from epithelial cells (black arrow) and connective tissues (yellow
arrow). In fibroadenoma (C), immunoperoxidase staining shows the (pro)renin was present in epithelial cells, myoepithelial cells, and connective tissues.
Control sections, omitting primary antibody, showed no immunostaining (B & D). Magnification  200.
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sand usually strong staining of most cells at intensity equivalent to
that seen in normal tissues to rather patchy, less positive staining
(Figure 4A). Nevertheless, (pro)renin expression was present in all
cases. Epithelial cells showed no immunoreactivity. The staining
reaction was abolished in the absence of primary antibody
(Figure 4B). In infiltrating ductal carcinoma grade II, (pro)renin
staining was absent from the majority of fibroblasts whereas
some epithelial cells showed positive staining (Figure 4C). When
present, myoepithelial cells showed positive staining. Control
sections, omitting primary antibody showed no immunostaining
(Figure 4D).
In grade III intraductal carcinoma, the cancer cells show little
(pro)renin staining, and instead, the fibroblasts frequently
show the greatest abundance of the antigen. The pattern of
Figure 4 (Pro)renin was localised in sections of formalin-fixed, paraffin-embedded ductal carcinoma in situ.( A) Immunoperoxidase staining shows the
antigen was present in myoepithelial cells (red arrow) and fibroblasts (yellow arrow). Staining was absent from epithelial (cancer) cells (black arrow). In
infiltrating ductal carcinoma grade II (C) (pro)renin was present in epithelial cells (black arrow). Staining was absent from majority of the fibroblasts (yellow
arrow). In infiltrating ductal carcinoma grade III (E), the antigen was present in fibroblasts (yellow arrow). Staining was absent from epithelial cells (black
arrow). In lobular carcinoma in situ (F) the antigen was present in fibroblasts (yellow arrow) with a very weak staining in epithelial cells (black arrow). Control
sections (B), (D), and (G), omitting primary antibody, showed no staining. Magnification  200.
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sstaining was variable, and ranged within individual sections
from uniform and strong, to a more patchy distribution
with weak or moderate staining which did not reach the intensity
seen in normal tissues. However, in some cases of poorly
differentiated invasive carcinoma, epithelial cells showed some
immunoreactivity with only a weak, patchy staining in fibro-
blasts (Figure 4E).
In lobular carcinoma in situ, positive staining for (pro)renin
was observed in myoepithelial cells and connective tissues
surrounding the lobules (Figure 4F). A very weak stain was shown
in the cytoplasm of the epithelial cells. The negative controls in the
absence of primary antibody showed no staining (Figure 4G).
Both MCF-7 (Figure 5A) and T47-D (Figure 5B) cell lines
showed strong prorenin expression. Control sections for MCF-7
cell line, gave no staining in the absence of primary antibody
(Figure 5C).
ACE These studies were carried out on frozen sections because
the primary antibody used was suitable for frozen sections, but not
for paraffin-embedded sections.
The results show that ACE was present in epithelial cells of
normal breast and virtually all the epithelial cells were positively
stained (Figure 6A). In all cases fibroblasts were negative. The
negative control shows no staining in the absence of the primary
antibody (Figure 6B).
In fibroadenoma too, epithelial cells, stained positively for ACE
(Figure 6C).
The connective tissues surrounding the ducts were completely
negative. The negative control shows no staining in the absence of
the primary antibody (Figure 6D).
In invasive ductal carcinoma grade III, ACE was expressed in the
epithelial cells but apparently less uniformly strong than in normal
tissue (Figure 6E and F). The staining intensity ranged from strong
in benign cells to moderate in poorly differentiated cancer cells.
The negative control shows no staining in the absence of the
primary antibody (Figure 6G). In all cases the connective tissue
showed no immunostaining.
DISCUSSION
It is increasingly clear that the the functions of the RAS extend
beyond its roles in sodium and potassium homeostasis and the
regulation of blood pressure and many studies have shown that it
has a wider significance. For example, Ang II also has trophic and
apoptotic activities in various cell types (Bedecs et al, 1997; Dinh
et al, 2001; Kaschina and Unger, 2003; Li et al, 2005). Furthermore,
immunolocalisation of the AT1 receptor also strongly suggests that
Ang II has a widespread role in maintenance of epithelial structure
and function (Vinson et al, 1995, 1997). Such functions may
include the regulation of water and electrolyte transport (Vinson
et al, 1995; Quan and Baum, 1996) as well as mitosis and tissue
differentiation (Bedecs et al, 1997; Li et al, 2005).
As Ang II and tRASs may have an important role in epithelial
tissue growth and modeling, it is possible that they may be
involved in cancer.
There is clear evidence for the presence of Ang II receptors in
different types of cancer. (Marsigliante et al, 1996; De Paepe et al,
2001; Deshayes and Nahmias, 2005; Suganuma et al, 2005). In
breast tissue, both AT1 and AT2 receptors are present, and the
AT1 is located in both lobular and ductal epithelial cells in normal
and benign breast tissues (Inwang et al, 1997), and increased AT1
receptor mRNA transcription has been shown in cancer as
compared with normal cells (Greco et al, 2002a), although receptor
expression may decrease in invasive carcinoma, compared with
hyperplasia or ductal carcinoma in situ (De Paepe et al, 2001). In
addition, AII has been shown to have an influence on breast
cancer cell metastasis throught its control of integrin expression
(Puddefoot et al, 2006). From this evidence, it is a clear possibility
that Ang II may be involved in the maintenance of normal breast
and epithelial tissue structure, and in vitro studies have shown
stimulation of proliferation in primary breast tissue cultures via
the AT1 receptor, together with the importance of the PKC
pathway involved (Greco et al, 2002b; Muscella et al, 2002).
There is evidence too for the existence of tRASs in cancer. The
expression of angiotensinogen, (pro)renin, ACE, and AT1 and AT2
receptors has been demonstrated in glioblastoma tumours and
glioblastoma cells in culture, in which renin has a direct role in
proliferation and/or survival (Juillerat-Jeanneret et al, 2004). In an
earlier study from this laboratory, (pro)renin gene transcription
was demonstrated in normal and abnormal breast tissue using
in situ hybridisation (Tahmasebi et al, 1998). (Pro)renin
transcription was found in nearly all samples, but there were
differences between normal and abnormal tissue. In normal breast
ducts, transcription was seen in myoepithelial cells and in
Figure 5 Immunoperoxidase staining of methanol-fixed MCF-7 (A) and
T47-D (B) breast cancer cells. (Pro)renin was present in both (black
arrow). There was no staining in the absence of primary antibody, shown
here for MCF-7 cells (C). Magnification  200.
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sfibroblasts, but none was found in the secretory epithelium. In
cancer, overall renin transcription was seemingly reduced with the
loss of myoepithelial cells, and it also became more sporadic in
fibroblasts.
To extend these studies, the present work was designed first to
confirm the presence of AT1 and AT2 receptor mRNA, together
with mRNA coding for components of the RAS. Quantitative
RT–PCR analysis revealed the transcription of AT1 and AT2
receptor mRNA in both normal and diseased human breast tissues
though AT1 mRNA was much more abundant in carcinoma than
in normal tissue (Figure 1A and B), thus supporting the growing
body of evidence discussed previously that increased AT1 receptor
expression may contribute to mammary carcinoma (Greco et al,
2002a). Angiotensinogen mRNA was present in very low amounts
compared with the liver and prorenin mRNA was present although
lower than in the kidney (Figure 2A), unsurprisingly, since
liver and kidney are usually considered to be the major sources
of these components (Mulrow, 1999; Kaschina and Unger, 2003).
However, confirming the previously reported in situ hybridisa-
tion data (Tahmasebi et al, 1998), there was significantly less
(pro)renin mRNA in carcinoma than in normal tissue. Finally, the
quantification of ACE mRNA showed that expression was present
in carcinoma, although again in lower amounts than in normal
tissue (Figure 2B).
Figure 6 ACE was invariably localised in epithelial cells in frozen sections of all tissue examined, illustrated here for normal breast tissue (A) fibroadenoma
(C) infiltrating ductal carcinoma grade III (E, F). Staining was absent from myoepithelial cells (red arrows) and connective tissues (yellow arrows). Control
sections, omitting primary antibody, showed no immunostaining (B, D, G). Magnification  200.
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sThis demonstrates that RAS components may be produced in
the breast, and leads to the question of their localisation.
In the present study, immunocytochemistry revealed that, in
most samples of normal breast tissue, (pro)renin was in present in
abundance in myoepithelial cells but, unlike its mRNA, it was
absent from connective tissues surrounding the ducts (Figure 3A).
This was also true in ductal and in lobular carcinoma in situ
(Figure 4A and F). Different staining patterns were seen in
fibroadenoma (Figure 3C), and in infiltrating ductal carcinoma
(Figure 4C) in which the antigen was weakly and sporadically
present in epithelial cells, but also more strikingly in fibroblasts as
well. Abundance of (pro)renin also varied according to the stage of
malignancy, suggesting that its expression varied inversely with
tumour grading. Thus, (pro)renin staining was still present in
fibroblasts, although at relatively low intensity (Figure 4E).
Together with previous data on the distribution of mRNA, which
in normal tissue was detected mostly in fibroblasts and myoepithe-
lium, the data suggest that (pro)renin, is formed in the fibroblasts
(and myoepithelium) and is transported from the connective
tissue site of synthesis, perhaps to myoepithelium (although
the myoepithelium is also a source), and possibly even to the
epithelium, though this is has only been faintly visible in some of the
abnormal samples (Figure 4C). In cancer, although, (pro)renin
mRNA and protein are both found in fibroblasts. This suggests that
the intimate association between fibroblasts, myoepithelium and
epithelium are essential for any such transfer to occur. Together
with the progressive loss overall of both (pro)renin mRNA and
protein, such physical disruption suggests that the system for local
Ang II generation is greatly impaired in cancer.
The localisation of ACE is especially important to the concept of
a local RAS supplying purely local requirements for Ang II. The
immunohistochemical results presented here shows that ACE is
largely distributed in the epithelial cells in human benign and
malignant breast tissues (Figure 6A, C, E and F). This distribution
matches that of the AT1 receptor, but is different from that of
(pro)renin. It suggests that Ang II in breast tissue is not necessarily
derived from the circulation and may originate from a local source.
Most importantly, it suggests that Ang II is produced directly in
the epithelium, the site at which it acts. Clearly it may be formed
from Ang I provided by renin activity in the myoepithelium. This
reveals a tightly organised RAS that is geared to the production of
hormone in the breast duct epithelium alone.
It is the apparently close coupling of (pro)renin and ACE
expression with the epithelial site of Ang II action that is so
compelling about the data presented here. As Ang II has numerous
functions in epithelial and other tissues, including the regulation of
mitosis and tissue differentiation, the observation that (pro)renin
transcription apparently fails in invasive carcinoma, crucially
suggests that here Ang II is not available to maintain these
functions. This has profound implications for our understanding
of cancer. We conclude that the local tRAS may be important for
the regulation of epithelial function in the breast. Such regulation
is lost as the renin producing fibroblasts and myoepithelium are
physically separated from the bulk of the proliferating cells. The
characteristic invasiveness of malignant cells may reflect this loss
of RAS control.
CONCLUSION
It is known that Ang II has a role in tissue structure and cell
proliferation, and its proliferative actions have been shown in
breast cancer cells. It is also known that the ductal epithelium is
abundantly supplied with AT1 and receptor, and, from the present
work, also with ACE. From previous and from the present work, it
is also now known that the epithelium is surrounded by fibroblasts
and myoepithelial tissue that transcribe and express (pro)renin,
and angiotensinogen mRNA is also present. These findings show
the possibility of a tRAS in the breast that is tightly coupled to the
site of action of the active hormone, Ang II. This system is
disrupted in cancer, leading to the possibility that failure of the
RAS, and Ang II production may contribute to the functional
phenotype of cancer cells.
A better understanding of the progression-specific alterations in
tRAS components in breast cancer could therefore be helpful in the
development of targeted therapies.
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